Vident Investment Advisory, LLC Novo Cure LTD Transaction History

Vident Investment Advisory, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $107,856 - $227,045	1,911 Added 40.57%	6,621 $398,000
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $71,337 - $95,187	1,115 Added 31.02%	4,710 $345,000
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $244,424 - $322,004	3,595 New	3,595 $270,000
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $273,441 - $384,227	-4,546 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $138,447 - $224,949	1,844 Added 68.25%	4,546 $341,000
Q3 2021 Nov 12, 2021	BUY	$116.17 - $194.55 $131,620 - $220,425	1,133 Added 72.21%	2,702 $314,000
Q2 2021 Aug 13, 2021	SELL	$130.4 - $225.58 $107,449 - $185,877	-824 Reduced 34.43%	1,569 $348,000
Q1 2021 May 14, 2021	SELL	$124.11 - $190.17 $18,492 - $28,335	-149 Reduced 5.86%	2,393 $316,000
Q4 2020 Feb 08, 2021	BUY	$112.16 - $174.14 $285,110 - $442,663	2,542 New	2,542 $440,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.79B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.